Présentation de l'entreprise
Exicure, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, where the primary objective is the development of advanced medical solutions. The company's operational focus involves the development of nucleic acid therapies designed to target ribonucleic acid against validated targets, a specialized approach in the biotech landscape. As a small-scale enterprise, Exicure, Inc. maintains a minimal workforce consisting of only 8 employees, reflecting the typical structure of early-stage biotechnology firms. The company's market capitalization is valued at $25.69M, while its annual revenue figures are not disclosed in the current reporting period. These valuation metrics, combined with the absence of significant operational revenue, indicate that the company remains in a pre-commercialization or early research phase where value is derived primarily from intellectual property and potential future clinical outcomes rather than current sales performance. The limited employee count further contextualizes the company's position as a resource-constrained entity relying heavily on external funding and strategic partnerships to advance its therapeutic pipeline.
Santé financière
The financial statements for Exicure, Inc. reveal a Net Income of $-4,946,000 over the trailing twelve-month period, with an EBITDA of $-9,875,000, indicating significant operational losses typical of biotechnology firms in the development stage. The Revenue (TTM) is listed as N/A, which, when compared to the substantial net losses, suggests that the company has not yet generated meaningful commercial sales to cover its extensive research and development expenses. Consequently, the gap between non-existent revenue and negative net income highlights a cost structure heavily weighted toward personnel, laboratory operations, and regulatory compliance costs before any product revenue is realized. The company's Free Cash Flow stands at $-4,212,750, demonstrating a consistent burn rate that limits financial flexibility and necessitates ongoing capital raises or asset monetization to sustain operations. Regarding profitability margins, the Gross Margin, Operating Margin, and Profit Margin are all reported at 0.0%, which is expected for a company with negligible revenue and significant overhead costs prior to market entry. The balance sheet shows a Cash position of $3.75M against total Debt of $176,000, creating a Debt to Equity ratio of 4.48, which technically indicates high leverage but represents a specific dynamic where debt is low relative to equity, yet the negative equity base distorts this standard metric. Despite the low absolute debt, the high Debt to Equity ratio and negative equity suggest a capital structure heavily reliant on equity financing rather than traditional debt instruments. Liquidity is assessed via a Current Ratio of 1.19, indicating that the company possesses slightly more current assets than current liabilities, providing a narrow margin of safety for meeting short-term obligations. Finally, the Return on Equity is -92.5% and the Return on Assets is -43.5%, metrics that reveal that management is currently unable to generate positive returns on the capital invested by shareholders or utilized in assets, reflecting the inherent risks of the biotechnology development cycle.
Évaluation de la valorisation
The valuation metrics for Exicure, Inc. present a complex picture due to the lack of profitability, with a P/E Ratio (TTM) of N/A and a Forward P/E of -5.23. The existence of a negative forward P/E ratio implies that the market is pricing in expectations of continued losses or a turnaround in earnings trajectory, rendering traditional earnings-based valuation multiples inapplicable for assessing fair value. The Price to Book ratio is recorded at 6.54, suggesting that the market values the company's equity at a significant premium over its book value, a common phenomenon in biotechnology where intangible assets and pipeline potential are not fully captured on the balance sheet. Alternative valuation measures such as the Price to Sales ratio, which is N/A, and the EV/EBITDA of -2.24, further complicate the assessment, as these metrics are distorted by the absence of sales and negative earnings. The stock's price volatility is captured by a Beta of 4.01, indicating that the share price is expected to be four times more volatile than the broader market, reflecting the high risk associated with small-cap biotechnology stocks. The share price has fluctuated significantly over the last year, with a 52-Week High of $12.85 and a 52-Week Low of $3.10, illustrating the wide range of investor sentiment regarding the company's development milestones and potential.
Growth & Income
The company's growth profile is constrained by the fact that Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, as the firm has not yet established a track record of recurring revenue or consistent earnings. Without positive revenue streams, it is impossible to calculate growth rates, and the absence of earnings growth implies that the company is not currently expanding profitability but rather focusing on survival and development. As a non-dividend payer, Exicure, Inc. does not distribute any cash to shareholders, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. This strategy aligns with the typical lifecycle of a pre-revenue biotechnology company, where earnings are theoretically reinvested into research and development rather than distributed, although the lack of positive earnings means there is no actual cash flow to reinvest. The overall growth and income profile for Exicure, Inc. is characterized by high risk and zero current income distribution, with all financial resources directed toward the development of nucleic acid therapies.